Aarti Pharmalabs Limited (NSE:AARTIPHARM) filed an intimation on 3 August 2026 under Regulation 30 of SEBI (LODR) Regulations, 2015, informing exchanges that an earnings conference call for investors and analysts has been scheduled for Monday, 10 August 2026, at 4:00 PM IST to discuss Q1 FY27 financial results.
Key Highlights
- The earnings conference call is scheduled for Monday, 10 August 2026, at 4:00 PM IST, hosted by 360 ONE Capital Market Research on behalf of the company.
- Chairman Rashesh Gogri, Vice Chairperson and Managing Director Hetal Gogri Gala, and CFO Piyush Lakhani will represent the management team on the call.
- Investors and analysts can participate via a Diamond Pass registration link or by dialling universal dial-in numbers, with international access available across multiple countries.
- The filing was made under Regulation 30 of SEBI (LODR) Regulations, 2015, by Company Secretary and Legal Head Jeevan Mondkar, ICSI M. No. A22565.
About the Company
Aarti Pharmalabs Limited (NSE:AARTIPHARM) is a Mumbai-headquartered pharmaceutical company engaged in the manufacture of active pharmaceutical ingredients (APIs), intermediates, and xanthine derivatives. The company operates manufacturing facilities and supplies products to domestic and international pharmaceutical markets. It is listed on NSE with scrip code 543748 on BSE and belongs to the broader pharma and healthcare sector.
Announcement in Detail
The intimation filed on 3 August 2026 confirms that Aarti Pharmalabs Limited has scheduled an earnings conference call for Monday, 10 August 2026, at 4:00 PM IST. The call will be convened to discuss the company's financial results for the first quarter of FY27, covering the period ending 30 June 2026. The event is being organised by 360 ONE Capital Market Research, which is coordinating registrations and dial-in access for participants.
The management team participating in the call will include Chairman Rashesh Gogri, Vice Chairperson and Managing Director Hetal Gogri Gala, and Chief Financial Officer Piyush Lakhani. Investors wishing to join may register through the Diamond Pass link provided in the invite or dial in using the universal numbers: +91 22 6280 1222 or +91 22 7115 8123. International toll-free access has been made available across countries including the USA, UK, Singapore, Japan, Australia, and others as listed in the filing.
Impact on Investors
Investors will note that this filing does not disclose any financial figures for Q1 FY27; those will be presented during the conference call on 10 August 2026. The filing shows that participation has been made accessible to a broad investor base, with both domestic dial-in numbers and international toll-free lines provided across more than fifteen countries, which may facilitate engagement from foreign institutional investors holding positions in AARTIPHARM.
Shareholders will observe that the presence of senior leadership, including the Chairman, Managing Director, and CFO, on the call indicates that the management intends to address Q1 results directly. The disclosed terms indicate no corporate action, no change in share capital, and no dilution event associated with this announcement. Investors are advised to review the official exchange filing for full participation details before the call.
Sector / Market Context
India's pharmaceutical industry is among the largest globally by volume, with API manufacturing forming a critical segment of the domestic supply chain. The Indian government has supported API self-reliance through Production Linked Incentive schemes targeting bulk drug parks and key starting materials, as reported by the Ministry of Chemicals and Fertilizers. Quarterly earnings disclosures from listed pharma companies like Aarti Pharmalabs provide the market with visibility into revenue trends, margin movements, and operational updates across API and intermediates segments, which are closely tracked by institutional investors and sector analysts.